Log in
Enquire now
‌

US Patent 12129300 Antibody variable domains targeting the NKG2D receptor

Patent 12129300 was granted and assigned to Dragonfly Therapeutics, Inc. on October, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Dragonfly Therapeutics, Inc.
Dragonfly Therapeutics, Inc.
0
Date Filed
November 3, 2023
0
Date of Patent
October 29, 2024
0
Patent Applicant
Dragonfly Therapeutics, Inc.
Dragonfly Therapeutics, Inc.
0
Patent Application Number
18501419
0
Patent Citations
‌
US Patent 7695936 Knobs and holes heteromeric polypeptides
0
‌
US Patent 7820166 Potent T cell modulating molecules
0
‌
US Patent 7879985 Antibodies against human NKG2D and uses thereof
0
‌
US Patent 7112324 CD 19×CD3 specific polypeptides and uses thereof
0
‌
US Patent 7235641 Bispecific antibodies
0
‌
US Patent 7575923 CD19xCD3 specific polypeptides and uses thereof
0
‌
US Patent 7635472 Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
0
‌
US Patent 7642228 Method for making heteromultimeric polypeptides
0
‌
US Patent 9963513 Method for the selection of antibodies against BCMA
0
‌
US Patent 10040853 Methods and compositions involving NKG2D inhibitors and cancer
0
•••
Patent Inventor Names
Bradley M. Lunde
0
Ann F. Cheung
0
Asya Grinberg
0
Bianka Prinz
0
Gregory P. Chang
0
William Haney
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12129300
0
Patent Primary Examiner
‌
Chun W Dahle
0

Find more entities like US Patent 12129300 Antibody variable domains targeting the NKG2D receptor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.